POLYETHYLENE GLYCOL 3350 - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for polyethylene glycol 3350 and what is the scope of patent protection?
Polyethylene glycol 3350
is the generic ingredient in twenty-two branded drugs marketed by Lannett Co Inc, Bayer Healthcare Llc, Ani Pharms, Annora Pharma, Aurobindo Pharma Ltd, Breckenridge Pharm, Elysium, Lgm Pharma, Mylan, Nexgen Pharma Inc, Novel Labs Inc, Nuvo Pharms Inc, Paddock Llc, Ppi-dac, Strides Pharma, Teva Pharms, L Perrigo Co, Braintree, Nostrum Labs Inc, Rising, Aurobindo Pharma Usa, Hospira, Norvium Bioscience, Vintage Pharms, Dynapharm, E Z Em, Goldline, and Sandoz, and is included in forty-one NDAs. Additional information is available in the individual branded drug profile pages.There is one drug master file entry for polyethylene glycol 3350. Sixty-five suppliers are listed for this compound. There is one tentative approval for this compound.
Summary for POLYETHYLENE GLYCOL 3350
US Patents: | 0 |
Tradenames: | 22 |
Applicants: | 28 |
NDAs: | 41 |
Drug Master File Entries: | 1 |
Finished Product Suppliers / Packagers: | 65 |
Raw Ingredient (Bulk) Api Vendors: | 218 |
Clinical Trials: | 305 |
What excipients (inactive ingredients) are in POLYETHYLENE GLYCOL 3350? | POLYETHYLENE GLYCOL 3350 excipients list |
DailyMed Link: | POLYETHYLENE GLYCOL 3350 at DailyMed |
Recent Clinical Trials for POLYETHYLENE GLYCOL 3350
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University Hospitals Cleveland Medical Center | Phase 4 |
Changchun GeneScience Pharmaceutical Co., Ltd. | Phase 1 |
Jinling Hospital, China | N/A |
Generic filers with tentative approvals for POLYETHYLENE GLYCOL 3350
Applicant | Application No. | Strength | Dosage Form |
⤷ Subscribe | ⤷ Subscribe | 2MG; 5MG | SOLUTION; ORAL AND TABLET; DELAYED RELEASE |
The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.
Pharmacology for POLYETHYLENE GLYCOL 3350
Drug Class | Osmotic Laxative |
Mechanism of Action | Osmotic Activity |
Physiological Effect | Stimulation Large Intestine Fluid/Electrolyte Secretion |
US Patents and Regulatory Information for POLYETHYLENE GLYCOL 3350
POLYETHYLENE GLYCOL 3350 Market Analysis and Financial Projection Experimental
More… ↓
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.